American Council on Science and Health12d
The FDA Finally Removes a Huge Barrier to an Effective Schizophrenia Medicine
For 35 years, the FDA has placed onerous restrictions on the only drug it has ever approved for treatment-resistant ...
MedPage Today25d
FDA Eliminates Barrier to Clozapine, Plans to End REMS Program
Following the advice of a nearly unanimous joint FDA advisory committee, the agency decided that clozapine's REMS program is no longer necessary to ensure that the benefits of the drug outweigh ...
The New York Times25d
F.D.A. Expands Access to Clozapine, a Key Treatment for Schizophrenia
By Ellen Barry The Food and Drug Administration has taken a crucial step toward expanding access to the antipsychotic medication clozapine, the only drug approved for treatment-resistant ...
Neurology Advisor16d
FDA Makes Access to Clozapine Easier for Patients With Schizophrenia
The FDA has eliminated the need for pharmacists to verify a patient's white blood cell count before dispensing the antipsychotic medication clozapine.